Gunther Kate, Fisher Teagan, Liu Dongli, Abbott Jason, Ford Caroline Elizabeth
Gynaecological Cancer Research Group, Lowy Cancer Research Centre, School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Sydney, Australia.
Gynaecological Research and Clinical Evaluation (GRACE) Unit, Royal Hospital for Women, Sydney, Australia.
Elife. 2025 May 20;14:e103825. doi: 10.7554/eLife.103825.
As a heterogenous disease with likely multiple pathogeneses and as-yet-undefined subtypes, progress in endometriosis treatment is currently limited by a lack of appropriate models and cohorts for research. Almost half of all publicly available datasets labelled as 'endometriosis' do not represent true disease as they are based on eutopic endometrium. Eutopic endometrial cells and tissues are frequently being used to represent endometriotic lesions, despite the unequivocal differences at both the tissue and cellular levels. As preclinical endometriosis research increases, it is important that the unique cellular and molecular profiles of endometrium and endometriosis are distinguished. Whilst each of these biospecimens can provide invaluable information to better understand disease aetiology and identify targets for diagnosis and treatment, it is imperative that the appropriate biospecimen and model are used to answer the relevant research question because endometriosis is not the endometrium.
作为一种可能具有多种发病机制且亚型尚未明确的异质性疾病,目前子宫内膜异位症的治疗进展受到缺乏合适的研究模型和队列的限制。几乎所有标记为“子宫内膜异位症”的公开可用数据集,有近一半并不代表真正的疾病,因为它们是基于在位内膜。尽管在位内膜细胞和组织在组织和细胞水平上存在明显差异,但它们经常被用来代表子宫内膜异位症病变。随着临床前子宫内膜异位症研究的增加,区分子宫内膜和子宫内膜异位症独特的细胞和分子特征非常重要。虽然这些生物样本中的每一种都可以提供宝贵的信息,以更好地了解疾病病因并确定诊断和治疗靶点,但必须使用合适的生物样本和模型来回答相关研究问题,因为子宫内膜异位症并非子宫内膜。